WASHINGTON, Feb 20 (Reuters) - Two U.S. drug safety reviewers have recommended that GlaxoSmithKline PLC’s (GSK.L) diabetes drug Avandia be pulled from the market after concluding it is more dangerous to the heart than a rival medicine, according to documents released on Saturday.
